PHARMACIELO LTD (PCLO.CA) Stock Fundamental Analysis

TSX-V:PCLO • CA71716K1012

0.06 CAD
+0.01 (+20%)
Last: Mar 2, 2026, 07:00 PM
Overview Stock Chart Technical Analysis Fundamental Analysis Analyst Ratings Earnings Estimates Financials Ownership News
Fundamental Rating

1

PCLO gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 34 industry peers in the Pharmaceuticals industry. PCLO may be in some trouble as it scores bad on both profitability and health. PCLO is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

0

1. Profitability

1.1 Basic Checks

  • In the past year PCLO has reported negative net income.
  • In the past year PCLO has reported a negative cash flow from operations.
  • In the past 5 years PCLO always reported negative net income.
  • PCLO had a negative operating cash flow in each of the past 5 years.
PCLO.CA Yearly Net Income VS EBIT VS OCF VS FCFPCLO.CA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 -10M -20M -30M -40M

1.2 Ratios

  • PCLO's Return On Assets of -74.31% is on the low side compared to the rest of the industry. PCLO is outperformed by 82.35% of its industry peers.
Industry RankSector Rank
ROA -74.31%
ROE N/A
ROIC N/A
ROA(3y)-64.09%
ROA(5y)-73.15%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PCLO.CA Yearly ROA, ROE, ROICPCLO.CA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2018 2019 2020 2021 2022 2023 2024 2025 0 500 -500

1.3 Margins

  • PCLO has a worse Gross Margin (3.13%) than 76.47% of its industry peers.
  • PCLO does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 3.13%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PCLO.CA Yearly Profit, Operating, Gross MarginsPCLO.CA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2018 2019 2020 2021 2022 2023 2024 2025 0 -1K -2K -3K -4K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

0

2. Health

2.1 Basic Checks

  • PCLO does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • PCLO has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, PCLO has more shares outstanding
  • The debt/assets ratio for PCLO is higher compared to a year ago.
PCLO.CA Yearly Shares OutstandingPCLO.CA Yearly Shares OutstandingYearly Shares Outstanding 2018 2019 2020 2021 2022 2023 2024 2025 50M 100M 150M
PCLO.CA Yearly Total Debt VS Total AssetsPCLO.CA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2018 2019 2020 2021 2022 2023 2024 2025 10M 20M 30M 40M 50M

2.2 Solvency

  • Based on the Altman-Z score of -32.58, we must say that PCLO is in the distress zone and has some risk of bankruptcy.
  • Looking at the Altman-Z score, with a value of -32.58, PCLO is doing worse than 94.12% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -32.58
ROIC/WACCN/A
WACC7.67%
PCLO.CA Yearly LT Debt VS Equity VS FCFPCLO.CA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2018 2019 2020 2021 2022 2023 2024 2025 0 20M -20M 40M

2.3 Liquidity

  • PCLO has a Current Ratio of 0.15. This is a bad value and indicates that PCLO is not financially healthy enough and could expect problems in meeting its short term obligations.
  • PCLO has a worse Current ratio (0.15) than 91.18% of its industry peers.
  • PCLO has a Quick Ratio of 0.15. This is a bad value and indicates that PCLO is not financially healthy enough and could expect problems in meeting its short term obligations.
  • PCLO has a Quick ratio of 0.09. This is amonst the worse of the industry: PCLO underperforms 91.18% of its industry peers.
Industry RankSector Rank
Current Ratio 0.15
Quick Ratio 0.09
PCLO.CA Yearly Current Assets VS Current LiabilitesPCLO.CA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2018 2019 2020 2021 2022 2023 2024 2025 5M 10M 15M 20M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

3

3. Growth

3.1 Past

  • The Earnings Per Share has grown by an impressive 57.30% over the past year.
  • Looking at the last year, PCLO shows a quite strong growth in Revenue. The Revenue has grown by 8.80% in the last year.
  • PCLO shows a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 38.20% yearly.
EPS 1Y (TTM)57.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.56%
Revenue 1Y (TTM)8.8%
Revenue growth 3Y26.81%
Revenue growth 5Y38.2%
Sales Q2Q%-33.1%

3.2 Future

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

  • No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
  • No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
PCLO.CA Yearly Revenue VS EstimatesPCLO.CA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2M 4M 6M
PCLO.CA Yearly EPS VS EstimatesPCLO.CA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 -0.1 -0.2 -0.3

More info and screens

Find the best growth stocksShow best growing peers

0

4. Valuation

4.1 Price/Earnings Ratio

  • PCLO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PCLO.CA Price Earnings VS Forward Price EarningsPCLO.CA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 0 0 0 0 0 0 0 0 0 0

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PCLO.CA Per share dataPCLO.CA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.02 -0.04 -0.06

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. Dividend

5.1 Amount

  • No dividends for PCLO!.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

PHARMACIELO LTD

TSX-V:PCLO (3/2/2026, 7:00:00 PM)

0.06

+0.01 (+20%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)02-26
Earnings (Next)N/A
Inst Owners0.18%
Inst Owner ChangeN/A
Ins Owners8.58%
Ins Owner ChangeN/A
Market Cap11.27M
Revenue(TTM)2.83M
Net Income(TTM)-6.42M
Analysts80
Price TargetN/A
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)N/A
EPS NY rev (3m)N/A
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 3.99
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-0.04
EYN/A
EPS(NY)N/A
Fwd EYN/A
FCF(TTM)-0.01
FCFYN/A
OCF(TTM)-0.01
OCFYN/A
SpS0.02
BVpS-0.08
TBVpS-0.08
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -74.31%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 3.13%
FCFM N/A
ROA(3y)-64.09%
ROA(5y)-73.15%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 0.15
Quick Ratio 0.09
Altman-Z -32.58
F-Score4
WACC7.67%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)57.3%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%52.56%
EPS Next YN/A
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)8.8%
Revenue growth 3Y26.81%
Revenue growth 5Y38.2%
Sales Q2Q%-33.1%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y24.63%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-149.32%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-155.49%
OCF growth 3YN/A
OCF growth 5YN/A

PHARMACIELO LTD / PCLO.CA FAQ

What is the ChartMill fundamental rating of PHARMACIELO LTD (PCLO.CA) stock?

ChartMill assigns a fundamental rating of 1 / 10 to PCLO.CA.


Can you provide the valuation status for PHARMACIELO LTD?

ChartMill assigns a valuation rating of 0 / 10 to PHARMACIELO LTD (PCLO.CA). This can be considered as Overvalued.


How profitable is PHARMACIELO LTD (PCLO.CA) stock?

PHARMACIELO LTD (PCLO.CA) has a profitability rating of 0 / 10.